The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

Combining oral upadacitinib and topical ruxolitinib cream showed superior repigmentation outcomes in progressive nonsegmental vitiligo compared to monotherapies. Significant improvements were observed ...

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...

Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), according to a multicenter study led by the Hospital del Mar Research ...

The latest announcement is out from Aprea Therapeutics ( (APRE) ).

Aldosterone dysregulation plays an important pathogenic role in hard-to-control hypertension. In several studies, baxdrostat, an aldosterone synthase inhibitor, reduced the seated systolic blood ...

Whether a person eats a cookie or devours the whole box could come down to the mood of microglia in their hypothalamus. Blocking activation of the region’s NLRP3 inflammasome could keep excessive ...

Novartis has scored the FDA’s approval for a second BTK inhibitor that’s for a non-cancer indication, teeing off a potential competition with Sanofi down the line. The FDA has blessed Novartis’ ...